<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03678142</url>
  </required_header>
  <id_info>
    <org_study_id>2018-01155; me18Eckstein</org_study_id>
    <nct_id>NCT03678142</nct_id>
  </id_info>
  <brief_title>DetectAB - Detecting Antibiotics</brief_title>
  <acronym>DetectAB</acronym>
  <official_title>DetectAB - Detecting Antibiotics - A Pilot Project</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Basel, Switzerland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The secretion of different kinds of antibiotic drugs in sweat is investigated. The
      concentration and pharmacodynamics of antibiotic drugs in sweat and blood will be compared.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 1, 2018</start_date>
  <completion_date type="Actual">October 31, 2019</completion_date>
  <primary_completion_date type="Actual">February 19, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in detection of last resort antibiotic Flucloxacillin in sweat.</measure>
    <time_frame>sample taken immediately before and 45 minutes after Flucloxacillin application</time_frame>
    <description>detection of Flucloxacillin in sweat by mass spectrometry (proof of concept).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in detection of last resort antibiotic Imipenem in sweat.</measure>
    <time_frame>sample taken immediately before and 60 minutes after Imipenem application</time_frame>
    <description>detection of Imipenem in sweat by mass spectrometry (proof of concept).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in detection of last resort antibiotic Vancomycin in sweat.</measure>
    <time_frame>sample taken immediately before and 5 hours after Vancomycin application</time_frame>
    <description>detection of Vancomycin in sweat by mass spectrometry (proof of concept).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in detection of last resort antibiotic Cefepim in sweat.</measure>
    <time_frame>sample taken immediately before Cefepim application and 2 hours, 4 hours, 6 hours, 8 hours after Cefepim application</time_frame>
    <description>detection of Cefepim in sweat by mass spectrometry (proof of concept).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>concentration (yg/ml) of last resort antibiotic Flucloxacillin in sweat.</measure>
    <time_frame>sample taken immediately before and 45 minutes after Flucloxacillin application</time_frame>
    <description>quantification of Flucloxacillin in sweat by mass spectrometry.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>concentration (yg/ml) of last resort antibiotic Imipenem in sweat.</measure>
    <time_frame>sample taken immediately before and 60 minutes after Imipenem application</time_frame>
    <description>quantification of Imipenem in sweat by mass spectrometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>concentration (yg/ml) of last resort antibiotic Vancomycin in sweat.</measure>
    <time_frame>sample taken immediately before and 5 hours after Vancomycin application</time_frame>
    <description>quantification of Vancomycin in sweat by mass spectrometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>concentration (yg/ml) of last resort antibiotic Cefepim in sweat.</measure>
    <time_frame>sample taken immediately before Cefepim application and 2 hours, 4 hours, 6 hours, 8 hours after Cefepim application</time_frame>
    <description>quantification of Cefepim in sweat and blood by mass spectrometry</description>
  </secondary_outcome>
  <enrollment type="Actual">17</enrollment>
  <condition>Antibiotic Drug Concentration in Sweat</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>analysis of last resort antibiotic drug (Flucloxacillin, Imipenem, Vancomycin or Cefepim) in sweat and blood</intervention_name>
    <description>blood draw (4.7 ml EDTA) and sweat sample taken (Macroduct Sweat Collecting System)</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        In- patients currently receiving intravenous antibiotic therapy (Cefepim, Flucloxacillin,
        Imipenem or Vancomycin) at University Hospital Basel/ Switzerland
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients

          -  Ability to understand the purpose of the study, provide signed and dated informed
             consent and qualify for therapeutic drug monitoring

          -  In-patients receiving intravenous therapy with last resort antibiotics Cefepim,
             Floxapen, Imipenem or Vancomycin for at least 24 hours

          -  Glomerular Filtration Rate &gt;/= 50 ml/Min

        Exclusion Criteria:

          -  Glomerular Filtration Rate &lt; 50 ml/Min
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jens Eckstein, PD Dr. med</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chief Clinical Medical Office</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Basel</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>August 21, 2018</study_first_submitted>
  <study_first_submitted_qc>September 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 19, 2018</study_first_posted>
  <last_update_submitted>December 10, 2019</last_update_submitted>
  <last_update_submitted_qc>December 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>antibiotic drug monitoring in sweat</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Vancomycin</mesh_term>
    <mesh_term>Imipenem</mesh_term>
    <mesh_term>Floxacillin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

